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The Cannabis sativa herb contains over 100 phytocannabinoid (pCB) compounds and has been 
used for thousands of years for both recreational and medicinal purposes. In the past two 
decades, characterisation of the body‟s endogenous cannabinoid (CB) (endocannabinoid, eCB) 
system (ECS) has highlighted activation of central CB1 receptors by the major pCB, 
9
-
tetrahydrocannabinol (
9
-THC) as the primary mediator of the psychoactive, hyperphagic and 
some of the potentially therapeutic properties of ingested cannabis. Whilst 
9
-THC is the most 
prevalent and widely studied pCB, it is also the predominant psychotropic component of 
cannabis, a property that likely limits its widespread therapeutic use as an isolated agent. In this 
regard, research focus has recently widened to include other pCBs including cannabidiol 
(CBD), cannabigerol (CBG), 
9
tetrahydrocannabivarin (
9
-THCV) and cannabidivarin 
(CBDV), some of which show potential as therapeutic agents in preclinical models of CNS 
disease. Moreover, it is becoming evident that these non-
9
-THC pCBs act at a wide range of 
pharmacological targets, not solely limited to CB receptors. Disorders that could be targeted 
include epilepsy, neurodegenerative diseases, affective disorders and the central modulation of 
feeding behaviour. Here, we review pCB effects in preclinical models of CNS disease and, 
where available, clinical trial data that support therapeutic effects. Such developments may 
soon yield the first non-
9
-THC pCB-based medicines. 
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Abbreviations 
AD, Alzheimer's disease; AED, anti-epileptic drugs; AEA, arachidonylethanolamide; 2-AG, 2-
arachidonylglycerol; CBC, cannabichromene; CBD, cannabidiol; CBDV, cannabidivarin; CB, 
cannabinoid; CBG, cannabigerol; CBN, cannibinol; DAGL , diacylglycerol lipase ; eCB, 
endocannabinoid; FAAH, fatty acid amide hydrolase; FST, forced swim test; GPCR, G-protein-
coupled receptor; HD, Huntington‟s disease; 6-OHDA, 6-hydroxydopamine; iNOS, inducible 
nitric oxide synthase; IN, interneuron; LPS, lipopolysaccharide; MES, maximal electroshock; 
MAGL, monoacyl glycerol lipase; MS, multiple sclerosis; NO, nitric oxide; NRS, numerical 
rating scale; PD, Parkinson's disease; pCB, phytocannabinoid; PC, Purkinje cell; rCBF, regional 
cerebral blood flow; SAD, seasonal affective disorder; SCE, standardised cannabis extract; 
SPST, stressful public-speaking test; TST, tail suspension test; 
9
-THC, 
9
-
tetrahydrocannabinol; 
9
-THCV, 
9
tetrahydrocannabivarin; TRP, transient receptor potential; 
TH+, tyrosine hydroxylase positive. 
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1. Introduction 
This review focuses on the emerging potential of phytocannabinoids (pCBs) to act as novel 
therapeutic agents in CNS disorders, in particular, as assessed by the use of preclinical in vivo 
animal models of CNS disease and available clinical trial data. Cannabis has been used 
medicinally and recreationally for thousands of years with early documentation of medicinal 
use in Chinese pharmacopoeias (Li & Lin, 1974) and the Indian Atharva Veda which accords 
cannabis status as one of five sacred plants (Touw, 1981). Early texts on herbal medicines were 
summarized by Dioscorides in ~60 A.D. and by Galen, who wrote of cannabis in the 2
nd
 
century A.D. in his De facultatibus alimentorum, “The leaves of this plant cure flatus – some 
people squeeze the fresh (seeds) for use in ear-aches. I believe that it is used in chronic pains”. 
Cannabis appeared in the 1788 New England Dispensatory, which retained large elements of 
Dioscorides herbal pharmacopoeia. Work of the 19
th
 century Irish physician, William 
O‟Shaughnessy, introduced medicinal use of cannabis to the UK (O'Shaughnessy, 1840), 
benefiting from the ascribed analgesic, anti-inflammatory, anti-emetic and anti-convulsant 
properties of the plant. However, medicinal use of cannabis fell out of favour in the early 20
th
 
century, largely due to concerns about psychoactivity and effects on behaviour, motor co-
ordination and memory and learning; such concerns lead to cannabis being removed from the 
British Pharmacopoeia in 1932 (Ashton, 2001; Kalant, 2001; Robson, 2001). However, it was 
still possible for UK physicians to prescribe cannabis for specific medicinal uses up to 1973, 
until prohibition by the Misuse of Drugs Regulation; in the current iteration of this Act (1985), 
cannabis is classified in Schedule 1, meaning that therapeutic use is effectively prohibited 
(Moffat, 2002). 
Despite these restrictions, interest in the pharmacology and potential therapeutic use of 
pCBs was engendered by the isolation of Δ9-THC and the subsequent discovery of other pCBs 
(Gaoni & Mechoulam, 1971; Mechoulam, 2005). Thereafter, the development of synthetic CB 
receptor ligands, such as Pfizer‟s CP55,940 in the 1980s, led to the identification of specific Δ9-
THC binding sites in the human CNS (Herkenham et al., 1990) and the identification and 
cloning of the first CB receptor, CB1 (Matsuda et al., 1990). These findings contributed to the 
discovery of the endocannabinoid (eCB) system (ECS) (a term introduced by Di Marzo & 
Fontana, 1995), which comprises the cannabinoid (CB) receptors, eCBs as their endogenous 
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ligands and the proteins responsible for eCB synthesis and degradation. Shortly thereafter, a 
second, principally peripheral, cannabinoid CB2 receptor was identified in 1993 (Munro et al., 
1993). Around the same time, arachidonic acid-derived, endogenous CB receptor ligands were 
identified, with the discovery of arachidonylethanolamide (AEA; Devane et al., 1992) and 2-
arachidonylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995). The first eCB 
degrading enzyme to be cloned was fatty acid amide hydrolase (FAAH; Cravatt et al., 1996), 
with a number of further degradation and synthetic enzymes being identified shortly afterwards 
(Patricelli & Cravatt, 2001); these enzymes have become a major target for therapeutic 
manipulation (Di Marzo, 2008, 2009). The discovery and characterisation of the ECS 
subserved a resurgence of interest in the pharmacological effects of the individual pCBs (Izzo 
et al., 2009; Pertwee, 2008). 
Despite the therapeutic potential afforded by the discovery of the ECS, licensed pCB-
based medicines have largely been restricted to the use of Δ9-THC in a subset of chronically ill 
patients. Synthetically produced Δ9-THC and its analogues are used clinically as dronabinol 
and nabilone, both used for attenuation of cancer chemotherapy-induced nausea and vomiting 
and appetite stimulation in HIV/AIDS patients. The widespread use of Δ9-THC is limited by 
psychoactivity and the associated abuse potential. Δ9-THC is a partial agonist at CB1 receptors 
whilst, by contrast, the anti-obesity agent, rimonabant, was the first clinically licensed CB1 
receptor antagonist. However, as a result of psychiatric side effects (depression and suicidality) 
reported following usage of higher doses (Christensen et al., 2007), rimonabant sales were 
suspended in 2008. Sativex (an approximately 1:1 mixture of Δ9-THC:CBD) is the first 
medicine derived from whole cannabis plant extracts to be licensed (at present in the UK, 
Canada, Spain, Germany, Denmark and New Zealand); specifically, to treat pain and spasticity 
in multiple sclerosis (MS) patients (Barnes, 2006; Perras, 2005). Most pertinently, the 
introduction of Sativex provided a precedent for the licensed therapeutic use of pCBs, a theme 
that will be further investigated here. The combination of CBD and 
9
-THC in Sativex is 
considered to reduce unwanted effects of 
9
-THC (Russo & Guy, 2006), most likely by CBD 
inhibiting the metabolism of 
9
-THC to the more psychoactive 11-OH-
9
-THC (Bornheim & 
Grillo, 1998), and there is evidence that CBD can oppose 
9
-THC effects in vivo (Malone et 
al., 2009; Vann et al., 2008). Thus, Sativex is an important development as it reduces 
9
-THC 
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central actions to produce a drug which is more tolerable and less prone to abuse (Schoedel et 
al., 2011). In this regard, it is also possible that 
9
-THC efficacy could be enhanced by 
„entourage‟ effects of other pCBs  present in the 9-THC and CBD extracts of which Sativex is 
comprised (Russo, 2011). Overall, the investigation of alternative, non-
9
-THC pCBs which 
lack psychotropic effects, but retain pharmacological activity, and the elucidation of their 
mechanisms of action has increasingly become a focus of the pharmaceutical industry and their 
potential to combat CNS disease is the major focus of this review. 
 
2. Synthesis and production of phytocannabinoids 
pCBs are lipid-soluble chemicals present in the resin secreted from trichomes that are 
abundantly produced by female plants of the Cannabis sativa herb. It is worth highlighting that 
pCBs are not so named because they share a common pharmacological target site or 
mechanism of action to eCBs and synthetic CBs, but due to their shared chemical structure. 
Within the plant, pCBs are synthesised from fatty acid precursors via a series of transferase and 
synthase enzymes (Figure 1). The two major pCBs, 
9
-THC and CBD, are derived from a 
common synthetic precursor, cannabigerol (CBG). From a pharmacochemical perspective, 
whilst 
9
-THC and CBD have pentyl side chains, major homologues are 
9
-
tetrahydrocannabivarin (
9
-THCV) and cannabidivarin (CBDV) respectively, with propyl side-
chains, derived from cannabigerovarin (CBGV). As discussed below, despite only small 
differences in chemical structure, these compounds appear to exhibit markedly different 
pharmacological properties. Other pCBs, such as cannabinol (CBN), are considered to be 
oxidation products. All pCBs are uniquely found in cannabis, with the total number of 
identified pCBs currently reported as over 100 (together with over 500 non-cannabinoid 
constituents; Elsohly & Slade, 2005; Mehmedic et al., 2010). The plant can be genetically 
manipulated to alter the relative ratios of the pCBs produced. Whilst this exploitable feature has 
been capitalised upon by the recreational drug market as a means to increase 
9
-THC yields, it 
is only more recently that the approach has been successfully used to develop a legitimate 
medicinal product. Thus, it is possible to use solely horticultural techniques to produce cloned 
plants („chemovars‟) which are uniformly enriched in different, specific pCBs (de Meijer et al., 
2003). Analogous to pharmaceutical synthesis of drug material, these processes follow FDA 
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botanical guidelines (Food and Drug Administration, 2004) to transform a raw material into a 
botanical drug substance as an active pharmaceutical ingredient, which can then be formulated 
into a botanical drug product, such as the standardised cannabis extracts (SCEs) used in 
Sativex. Importantly, modulation of the ratio of specific pCBs in different SCEs may not only 
offer therapeutic potential dependent on the nature of the target disease, but also provide a 
viable intellectual property model to justify pharmaceutical industry development of cannabis-
based medicines. 
 
3. Phytocannabinoid molecular targets and mechanisms of actions 
3.1. The endocannabinoid system (ECS)  
The detailed characterisation of the ECS, including the molecular determination of CB receptors 
and the metabolic pathways and actions of eCBs, initially provided a useful framework to 
discuss pCB actions. CB receptor activity can be modulated directly by ligand binding, or 
indirectly, via modulation of eCB levels (for example by enzyme inhibition). CB1 and CB2 
receptors are seven-transmembrane spanning proteins of the rhodopsin G-protein-coupled 
receptor (GPCR) family A, sharing 44% sequence identity overall with 68% identity in their 
transmembrane domains (Munro et al., 1993; Pertwee et al., 2010). The pertussis toxin-sensitive 
nature of CB receptor-induced adenylyl cyclase inhibition suggested a predominant coupling to 
inhibitory G i/o subunits (Felder et al., 1993). Within the CNS, CB1 receptors are largely 
localized to presynaptic terminals, particularly in the cerebral cortex, hippocampus, cerebellum 
and basal ganglia, with little evidence of postsynaptic expression (Herkenham et al., 1990; Tsou 
et al., 1998). Activation of presynaptic CB1 receptors, via the retrograde release of eCBs 
produced by postsynaptic cells following periods of sustained excitation (Alger & Kim, 2011), 
causes a inhibition of neurotransmitter release and dynamically modulates both excitatory and 
inhibitory neuronal activity in the CNS (Chevaleyre et al., 2006; Ma et al., 2008; Guggenhuber 
et al., 2010). Recent studies have identified CB2 protein and mRNA at sites in the CNS (Van 
Sickle et al., 2005; Onaivi et al., 2006). CB2 receptors are expressed in the CNS on astrocytes, 
microglia and cerebromicrovascular endothelial cells (Golech et al., 2004; Nunez et al., 2004; 
Rivers & Ashton, 2010) and such expression could play a role in pathogenesis and treatment of 
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conditions involving neuroinflammation and neurodegeneration (Arevalo-Martin et al., 2008; 
Cabral & Griffin-Thomas, 2009). 
It is becoming apparent that pCBs exhibit a considerable range of affinities for the CB1 
receptor (Figure 2; Kreitzer & Stella, 2009; Pertwee, 2008; Pertwee et al., 2010). Δ9-THC is 
believed to exert the majority of its actions in the CNS as a partial agonist at CB1 receptors 
(Howlett, 2002). Amongst other pCBs, Δ9-THCV is one of the few compounds known to exert 
direct and relatively potent effects at CB receptors, leading to its description as a CB1 antagonist 
(although with evidence of CB1 agonist properties at higher doses (>10 mg/kg in vivo)) and, also, 
a potent CB2 receptor partial agonist (Thomas et al., 2005; Dennis et al., 2008; Ma et al., 2008; 
Pertwee, 2008; Bolognini et al., 2010). Interestingly, CBD shows only low CB receptor binding 
affinity (Bisogno et al., 2001; Pertwee, 2008; Jones et al., 2010; Figure 2), but has been shown to 
antagonise the action of synthetic CB ligands at CB1 and CB2 receptors (Pertwee et al., 2002; 
Thomas et al., 2007). In general, current knowledge for actions of other pCBs at CB receptors 
remains incomplete; however, CBG has been reported to exhibit only low CB receptor potency 
(Figure 2; Cascio et al., 2010), but antagonises the effects of CB1 ligands in [
35
S]GTP S binding 
assays (Cascio et al., 2010). Moreover, recent pharmacological evidence has shown that the CB1 
receptor contains an allosteric binding site (Price et al., 2005; Horswill et al., 2007) and the 
allosteric CB1 receptor antagonist, PSNCBAM-1 exerts agonist-dependent effects on inhibitory 
synaptic transmission in the CNS (Wang et al., 2011). The identification of an allosteric CB1 site 
promises to drive the characterisation and development of novel probes and drug candidates, 
although any potential for pCBs to act via such sites is not known as yet. Overall, whilst these 
studies demonstrate that selected pCBs (i.e. Δ9-THC and Δ9-THCV) exert effects via direct 
interaction with CB receptors, other pCBs thus far investigated exhibit an alternative, but 
potentially therapeutically exploitable, pharmacology (Izzo et al., 2009). 
More recent evidence has revealed that pCBs can exert effects via modulation of eCB 
tone in the CNS. The principal targets so far identified are the 2-AG biosynthetic enzyme, 
diacylglycerol lipase  (DAGL ), and the catabolic enzymes, FAAH and monoacyl glycerol 
lipase (MAGL), predominantly responsible for AEA and 2-AG hydrolysis, respectively (Di 
Marzo et al., 2005). A number of prominent non-Δ9-THC pCBs show micromolar potency as 
ECS enzyme inhibitors in vitro: CBDV inhibits DAGL  CBD inhibits FAAH whilst CBG and 
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cannabichromene (CBC) inhibit MAGL (Watanabe et al., 1996; Rakhshan et al., 2000; Bisogno 
et al., 2001; De Petrocellis et al., 2011). In a related fashion, micromolar concentrations of CBG, 
CBC, CBDV and CBN all inhibit cellular uptake of AEA (De Petrocellis et al., 2011). Whilst the 
functional effects of pCBs on eCB tone and their pharmacological relevance remain to be fully 
determined, this evidence suggests that pCB effects in the CNS are not limited to components of 
the ECS and such distinctions are discussed below. 
 
3.2. Non-CB receptors and ion channel targets of pCBs  
In addition to effects on the ECS, evidence arising from pharmacological experiments in 
recombinant cell lines and CB receptor knock-out animals strongly supports pCB actions at 
alternative, non-CB receptor sites. Orphan GPCRs, most notably GPR55 and GPR119, have 
been identified as potential novel CB receptors on the basis of affinity for some CB ligands 
(Pertwee, 2007; Ross, 2009; Pertwee et al., 2010). However, it is not yet clear whether GPR55 
is a bona fide CB receptor, as it possesses low sequence homology to CB1 and CB2 and the 
endogenous phospholipid, lysophosphatidylinositol, also has affinity for the receptor 
(Nevalainen & Irving, 2010; Sharir & Abood, 2010). There are, thus far, limited reports of pCB 
activity at GPR55; for example, 
9
-THC has a weak agonist effect, whilst reports of CBD as a 
GPR55 antagonist appear to be largely assay-dependent (Pertwee et al., 2010). 
  An interesting emerging concept is that pCBs can also activate non-CB metabotropic 
GPCRs. In particular, CBD has been widely reported to act as a 5-HT1A agonist (Russo et al., 
2005; Magen et al., 2010; Ledgerwood et al., 2011) and also to have actions sensitive to 
adenosine A2A receptor antagonists (Magen et al., 2009). Another recent study has shown that 
CBG is an agonist at α2-adrenoceptors and an antagonist at 5-HT1A receptors (Cascio et al., 
2010). It is also becoming clear that pCBs have the potential to affect neuronal excitability via 
the modulation of ligand-gated and voltage-gated ion channels (Pertwee, 2008; Pertwee et al., 
2010). In particular, recent studies have highlighted the effects of a number of pCBs, including 
CBD, CBG, CBC and CBN, at different transient receptor potential (TRP) (ligand-gated non-
selective cation) channels. CBD has been widely reported to activate TRPV1 and TRPV2 
channels (Costa et al., 2004; De Petrocellis et al., 2008; Qin et al., 2008); interestingly, TRPV1 
co-localises with CB1 receptors in mouse brain (Cristino et al., 2006). More recently, CBG, 
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CBGV and 
9
-THCV have also been shown to activate TRPV1 channels (De Petrocellis et al., 
2011). Similarly, 
9
-THC, CBD, CBGV, CBG, 
9
-THCV and CBDV have all been shown to 
activate rat TRPV2 channels (De Petrocellis et al., 2011). pCB effects at TRPV1 and TRPV2 
channels typically manifest at low micromolar concentrations, which does question, but not 
exclude, their pharmacological relevance; for example, reported actions included channel 
desensitization, akin to the proposed therapeutic action for agonists such as capsaicin. CBD, 
CBC, and CBN are more potent (nanomolar concentration) agonists at rat TRPA1 channels and 
also desensitise the channel (De Petrocellis et al., 2011). CBD, CBG, CBN, 
9
-THCV, CBDV 
and CBGV (at low micromolar concentrations) all also act as antagonists at rat TRPM8 
channels (De Petrocellis et al., 2011). CBD has also been demonstrated to act at ligand-gated 
receptors, being a putative allosteric inhibitor of 5-HT3A receptors (Yang et al., 2010) and an 
allosteric and direct activator of inhibitory glycine receptors (Ahrens et al., 2009; Foadi et al., 
2010). There is growing evidence that synthetic CBs and eCBs can modulate voltage-
dependent Ca
2+
, K
+
 and Na
+
 channels (Demuth &Molleman, 2006; Oz, 2006; Pertwee et al., 
2010); at present, evidence for similar pCB actions at ion channels is limited. However, Δ9-
THC and CBD have recently been shown to inhibit CaV3.1, CaV3.2 and CaV3.3 (T-type) Ca
2+
 
channels (Ross et al., 2008). Therefore, both ligand-gated and voltage-dependent ion channels 
may be targeted by pCBs and it will be important to augment such studies using in vitro 
electrophysiology to determine the functional effects of pCBs on neuronal excitability and 
whether such effects are seen at pharmacologically relevant concentrations. 
 
3.3 Neuroprotection and CNS immune function 
pCBs are known to protect neurons from neurotoxic stimuli or neurodegeneration via a range of 
properties which may include ligand action at CB receptors, innate antioxidant properties and 
effects on the CNS immune system. 
9
-THC has been shown to possess CB1-dependent 
neuroprotective effects in excitotoxicity assays in vitro (Abood et al., 2001; Gilbert et al., 2007) 
and in vivo (Chen & Buck, 2000; van der Stelt et al., 2001; El-Remessy et al., 2003; Zani et al., 
2007). However, several studies have highlighted CB receptor-independent mechanisms by 
which 
9
-THC and other pCBs can protect neurons. Most clearly described is the antioxidant 
capacity of pCBs. A study in 1998 first highlighted the CB1 receptor-independent antioxidant 
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properties of 
9
-THC and CBD (Hampson et al., 1998), demonstrating their ability to protect rat 
cortical neurons from glutamate receptor-mediated excitotoxicity, which is known to be 
mediated by reactive oxygen species. El-Remessy et al. (2003) showed that both 
9
-THC and 
CBD protected rat retinal neurons against NMDA-induced neurotoxicity in vivo, decreasing 
levels of peroyxnitrite and associated oxidative stress-related compounds.  
pCBs are also able to modulate immune cells and the production of immune factors in the 
CNS in experimentally-induced models of neurodegenerative disorders. The primary immune 
cells in the CNS are microglia which provide support to neural cells; in neurodegenerative 
diseases, microglia are co-localised to sites of neuronal death (Ramirez et al., 2005; Lull & 
Block, 2010). Agonism of CB2 receptors on microglia attenuates their further activation (Carrier 
et al., 2004; Kreitzer & Stella, 2009; Stella, 2010), limiting ability of microglia to release pro-
inflammatory agents including tumour necrosis factor  and nitric oxide (NO) (Ehrhart et al., 
2005; Ramirez et al., 2005). Correspondingly, the agonist properties of both 
9
-THC and 
9
-
THCV at CB2 receptors have been implicated in neuroprotection in vivo (Tourino et al., 2010; 
Garcia et al., 2011). CBD has also been shown to be anti-inflammatory by limiting ATP-induced 
increases in intracellular Ca
2+
 levels and NO production in cultured microglial cells (Martin-
Moreno et al., 2011). An anti-inflammatory effect of CBD was also observed in 
lipopolysaccharide (LPS)-injected mice due to inhibition of adenosine uptake (Carrier et al., 
2006); a similar effect was seen in vitro and in rat retina insulted by LPS (Liou et al., 2008). 
Production of pro-inflammatory cytokines by LPS–stimulated cultured microglial cells was 
inhibited by CBD via a decreased activity of NF- B, but increased activation of STAT3 (Kozela 
et al., 2010). Additionally, CBD decreased inducible nitric oxide synthase (iNOS) expression 
and TNF  levels in a mouse model of LPS-induced inflammation (Ruiz-Valdepenas et al., 
2011).  
In summary, it is clear that pCBs exhibit a range of apparently neuromodulatory, 
neuroprotective, anti-oxidant and anti-inflammatory properties, including effects on biochemical 
pathways that could complement their effects on receptors, ion channels and enzymes to achieve 
an overall therapeutic aim. The utility of such effects is discussed hereafter in an examination of 
pCB effects in animal models of CNS disease and human clinical trials. 
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4. Effects of phytocannabinoids in CNS disorder, disease and dysfunction 
4.1 Phytocannabinoids in the treatment of epilepsy and hyperexcitability disorders  
4.1.1.Historical background 
Cannabis has played a historical role in the treatment of hyperexcitability disorders, a 
prominent example being epilepsy, where the first evidence of therapeutic use was attributed to 
the Arabic scholar al-Mayusi in 1100AD (Lozano, 2001), although additional evidence to 
support such use can be found in both Ayurvedic and Islamic medicine (Russo, 2005; Russo 
2007). Cannabis use was again noted in the 15
th
 century, when the historian Ibn al-Badri wrote 
that when “the epileptic son of the caliph's chamberlain” was treated with cannabis “it cured 
him completely, but he became an addict who could not for a moment be without the drug” 
(Mechoulam, 1986), a predictable consequence given the chronic, progressive nature of 
epilepsy. Thereafter, it was not until after William O‟Shaughnessy successfully treated seizures 
in an infant using cannabis tincture (O'Shaughnessy, 1840) that further reports emerged 
describing attempts to use cannabis to treat seizures (McMeens, 1856, 1860; Reynolds, 1868). 
  In the 1970s, effects of several common cannabis constituents on seizure states were 
further examined using the maximal electroshock (MES) model (Karler et al., 1973; Karler et 
al., 1974b; Turkanis et al., 1974). These early studies revealed an order of potency of 
9
-
THC>CBD>CBN although, interestingly, the authors asserted that CBD had the greatest 
protective index, comparable to the, then widely used, anticonvulsant phenobarbital (for review, 
see Karler & Turkanis, 1981; Karler & Turkanis, 1976). These studies supported a number of 
small-scale human trials, individual case studies and surveys that investigated herbal cannabis 
and isolated pCB use for seizure control (Table 1). Whilst these studies stimulated a limited 
number of pre-clinical investigations (Chiu et al., 1975; Karler et al., 1974a; Smiley et al., 
1976; Thomson & Turkanis, 1973; Turkanis et al., 1977; Turkanis & Karler, 1975; Turkanis & 
Karler, 1981a; Turkanis & Karler, 1987; Turkanis et al., 1991; Turkanis et al., 1979), the 
complex nature of epilepsy and the diverse model- and species-specific effects of cannabis (and 
individual pCBs) rendered the elucidation of mechanisms of action difficult, particularly in the 
case of 
9
-THC, upon which attention had been largely focussed (Martin & Consroe, 1978; 
Consroe & Fish, 1980). 
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 The renewed interest in potential therapeutic applications of pCBs included 
investigations using in vitro models of epileptiform activity (Wilkinson et al., 2003; Whalley et 
al., 2004) and, subsequently, in vivo models of seizure. 
9
-THC clearly affects seizure states 
and susceptibility in preclinical models (Lutz, 2004; Boggan et al., 1973) via well-known 
effects at central CB1 receptors (Shen & Thayer, 1999). However, 
9
-THC (and other CB1 
agonists) often exhibit contradictory pro- and anti-convulsant effects in clinical cases (Table 1) 
and preclinical models (Karler & Turkanis, 1980; Turkanis & Karler, 1981b; Turkanis & Karler, 
1982; Consroe & Mechoulam, 1987; Wallace et al., 2001; Fish et al., 1983). Together with 
psychotropic side effects, such contradictory effects likely limit or prohibit 
9
-THC‟s 
widespread therapeutic use as an isolated agent. However, many surveys continue to report 
medicinal cannabis use for the control of seizures, which lends credence to an overall 
conclusion that the presence of 
9
-THC in SCEs per se does not necessarily represent a de 
facto pro-convulsant risk. Moreover, in some clinical cases (Table 1), 
9
-THC at higher doses 
can be an effective anticonvulsant, but is limited by extensive psychoactive side-effects. 
Overall, whilst the variability of 
9
-THC‟s effects may represent a limiting factor, growing 
evidence supports attenuation of undesirable 
9
-THC effects by pCB- and non-pCB 
components of cannabis (Russo, 2011), so improving its therapeutic index and legitimising the 
case-by-case use of 
9
-THC-based medicines (e.g. „medical marijuana‟) against seizures, as is 
currently the case in Canada and some US states.  
 
9
-tetrahydrocannabivarin (
 9
-THCV) in hyperexcitability 
9
-THCV has demonstrated interesting potential for use in the treatment of hyperexcitability 
states. Following identification and characterisation of 
9
-THCV as a CB1 receptor antagonist 
(Thomas et al., 2005; Dennis et al., 2008), the increase of inhibitory synaptic transmission in 
cerebellar brain slices represented the first description of functional
9
-THCV effects in the 
CNS (Ma et al., 2008). In the latter study, 
9
-THCV (5-58 M) significantly increased 
GABAergic transmission at interneuron-Purkinje cell (IN-PC) synapses in patch clamp 
electrophysiological recording; complementary use of multi-electrode array (MEA) recording 
demonstrated that 
9
-THCV significantly reduced spontaneous unit and multi-unit PC spike 
firing (Figure 3; Ma et al., 2008). 
9
-THCV modulated the effects of the CB agonist 
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WIN55,212-2 and 
9
-THCV actions were abolished by the GABAAR antagonist, bicuculline. 
Overall, these data were consistent with 
9
-THCV antagonising CB1 receptors at IN-PC 
presynapses to increase inhibitory neurotransmission (either via a blockade of eCB action or by 
attenuation of constitutive CB1 activity) leading to a reduction in PC excitation. The ability of 
9
-THCV to modulate PC output contrasts with the well-known adverse (partial) agonist 
effects of 
9
-THC, which induces deficits in motor coordination in vivo (DeSanty & Dar, 
2001a; DeSanty & Dar, 2001b; Patel & Hillard, 2001), a reported effect of cannabis 
intoxication. From the perspective of hyperexcitability states, the effects of 
9
-THCV in 
increasing inhibition in the cerebellum is consistent with a desirable pharmacological profile 
for use in spinocerebellar ataxias, a progressive and presently pharmacologically untreatable 
group of hyperexcitability disorders (Paulson, 2009), although pre-clinical in vivo animal 
studies in this specific therapeutic area have yet to be undertaken.  
More recently, 
9
-THCV was reported to exhibit in vitro anti-epileptiform and in vivo 
anticonvulsant properties (Hill et al., 2010a). In this study, 
9
-THCV (>20 M) significantly 
reduced burst complex incidence and the amplitude and frequency of paroxysmal depolarizing 
shifts (PDSs) induced by use of Mg
2+
-free media (which activates excitatory glutamatergic 
NMDA receptors) in piriform cortical brain slices; 
9
-THCV also inhibited the propagation of 
this epileptiform activity. This investigation also showed that pre-incubation of piriform 
cortical slices with 10 M 
9
-THCV significantly reduced neuronal excitability in response to 
Mg
2+
-free media, consistent with the hypothesis that exposure to 
9
-THCV may be 
prophylactic in preventing hyperexcitability. In the pentylenetetrazole model of acute 
generalised seizures, 
9
-THCV (0.25 mg/kg) significantly reduced seizure incidence, although 
failing to affect other commonly employed seizure measures (Hill et al., 2010a). It has been 
shown recently that in vivo seizure states may be disrupted as a result of a CB1 agonist-
mediated desynchronisation of pathological neuronal firing (Mason & Cheer, 2009), similar 
desynchronisation could also hold true for CB1 antagonist-mediated blockade of eCB tone; 
such a hypothesis is consistent with known 
9
-THCV effects upon the propagation of 
epileptiform activity (Hill et al., 2010a). 
Overall, although the concept of presynaptic CB1 receptor-mediated inhibition of 
excitatory neurotransmitter release being consistent with anti-epileptiform effects is intuitively 
 15 
 
clear (Lutz, 2004), a mechanism underlying anticonvulsant 
9
-THCV effects, alongside other 
confirmatory and contradictory reports of synthetic CB1 antagonist effects in seizure models 
(Echegoyen et al., 2009; Kozan et al., 2009), is not immediately apparent. However, when a 
preferential CB receptor ligand effect is considered, such as that described above for inhibitory 
IN-PC synapses in the cerebellum (Ma et al., 2008) or excitatory terminals in the hippocampus 
(Monory et al., 2006), it becomes clear that effects on neuronal excitability obtained via CB1 
modulation are likely to be highly dependent upon the sub-population of neurons (i.e. 
inhibitory or excitatory) preferentially affected (Lutz, 2004). 
 
4.1.3 Cannabidiol (CBD) in hyperexcitability 
CBD remains the only isolated, non-
9
-THC pCB to have been investigated for anticonvulsant 
effects in human subjects to date (Table 1). As early as 1977, CBD effects upon seizure states 
in animals were investigated using MES and audiogenic seizures and compared with those of 
standard anti-epileptic drugs (AEDs) including phenytoin, phenobarbital, carbamazepine, and 
ethosuximide (Consroe & Wolkin, 1977a). CBD (>100 mg/kg) administered alone was an 
effective anticonvulsant in both seizure models, but had differential effects when co-
administered with standard AEDs, enhancing the anticonvulsant effects of phenytoin or 
phenobarbital, but diminishing the effects of chlordiazepoxide, clonazepam, trimethadione or 
ethosuximide (Consroe & Wolkin, 1977a; Consroe & Wolkin, 1977b). A potential advantage of 
CBD is that, unlike 
9
-THC, no evidence of contradictory central excitatory or pro-convulsant 
effects exists (Chiu et al., 1979). In electrically kindled limbic seizures in rats, CBD (0.3-3 
mg/kg) raised epileptic after-discharge threshold in a manner consistent with the known effects 
of phenytoin in this model, but, in common with the effects of ethosuximide, also decreased 
after-discharge amplitude, duration and propagation (Turkanis et al., 1979). It is notable that, 
compared to phenytoin and ethosuximide, the authors concluded that “CBD was the most 
efficacious of the drugs tested against limbic ADs [after-discharges] and convulsions”. CBD 
had a selective depressant effect upon evoked cortico-limbic responsiveness in non-epileptic 
states (Turkanis & Karler, 1981a). CBD (60 mg/kg) had no discernible effect in rats rendered 
chronically epileptic by cortical implantation of cobalt, which manifests as partial seizures with 
secondary generalisation (Colasanti et al., 1982), whilst 
9
-THC was found to exert a short 
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term (~1 day) anticonvulsant effect. It is however noteworthy that cobalt-induced seizures share 
many common features with human absence seizures (Loscher, 1997) and, as such, have little 
in common with seizure models in which CBD exerts a significant anticonvulsant effect. Such 
model-specific effects were also exemplified using a battery of acute models of seizures 
induced by agents that included MES, 3-mercaptoproprionic acid, picrotoxin, isonicotinic acid 
hydrazine, bicuculline, pentylenetetrazole and strychnine (Consroe et al., 1982). Here, CBD 
(50-400 mg/kg with most notable effects occurring at >100 mg/kg) was equally effective in the 
MES and all GABA inhibition-based models, but entirely ineffective against strychnine-
induced convulsions. 
More recently, CBD effects upon chemically-induced epileptiform activity in acute 
hippocampal brain slices have been described (Jones et al., 2010). Here, CBD significantly 
reduced measures of spontaneous epileptiform activity induced either by use of Mg
2+
-free 
media, or by the application of the K
+
 channel blocker, 4-aminopyridine. In the Mg
2+
-free 
model, CBD (100 M) decreased epileptiform local field potential burst amplitude and duration. 
In the 4-aminopyridine model, CBD (100 M) decreased burst amplitude in CA1 only, burst 
duration in CA3 and dentate gyrus, and burst frequency in all regions. The same report also 
recapitulated the previous investigation of CBD effects upon pentylenetetrazole-induced, acute, 
generalised seizures (Consroe et al., 1982) and found that CBD (100 mg/kg) significantly 
decreased mortality and the incidence of the most severe seizure states. Finally, in this study, 
CBD was shown to exhibit only low affinity for CB1 receptors in radioligand binding studies 
and no agonist activity in GTP S binding assays, supporting a CB1 receptor independent 
mechanism of anticonvulsant action (Jones et al., 2010; see also Figure 2). 
Taken together, CBD exhibits the most reliable anticonvulsant effects of currently tested 
pCBs. Moreover, in contrast to clinically used anticonvulsants, CBD exhibits no neurotoxic or 
motor side-effects as assessed by standard rotarod tests (Consroe et al., 1981; Martin et al., 
1987). Overall, recent data more fully supports the proposal for CBD potential in the treatment 
of grand mal, cortical focal, partial, but not absence seizures. In this regard, CBD exhibits a 
potential useful polypharmacology that may benefit modulation of neuronal excitability (Figure 
4). In addition to the epilepsy-specific actions described above, CBD has been shown to reduce 
intracellular Ca
2+
 levels in hippocampal neurons under conditions modelling increased 
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excitability (Ryan et al., 2009). Such actions occur via an inhibitory action on mitochondria Ca
2+
 
stores and are consistent with CBD possessing further useful actions to reduce hyperexcitability 
in the CNS. 
 
4.1.4 Summary 
Overall, 
9
-THC effects in hyperexcitability disorders can be unpredictable and, based on the 
extant evidence, effects are likely to be specific to the disorder and the individual which is, 
given 
9
-THC‟s psychoactive effects and the idiopathic and/or cryptogenic natures of most 
epilepsies, unsurprising. This, together with notable side effects, limits 
9
-THC‟s widespread 
therapeutic use, although sufficient case studies have reported apparent benefit and so prevent 
the drawing of a single definitive conclusion applicable to all epilepsies. We have used 
complementary in vitro electrophysiological techniques to provide the first descriptions of non-
9
-THC pCB effects in hyperexcitability in the CNS; in particular, effects of 
9
-THCV and 
CBD have been translated into preclinical in vivo seizure models and shown to possess 
therapeutic potential. Whilst 
9
-THCV shows some promise in this regard, its clinical utility 
may be limited to pathophysiological conditions associated with CB1 receptors preferentially 
located on inhibitory synapses. By contrast, there is clearly compelling evidence to support 
further investigation of CBD effects in human hyperexcitability states, either as an adjunct or 
standalone treatment. More broadly, whilst 
9
-THCV and CBD‟s effects in seizure models cast 
new light upon the potential therapeutic use of cannabis constituents for the treatment of 
hyperexcitability disorders, it is notable that they still represent a minority of the pCBs present 
in cannabis. Consequently, further studies are required to assess whether other, as yet 
uninvestigated, pCBs modulate seizure activity from both the perspective of AED development 
and risks associated with cannabis use (Wilkinson et al., 2003; Hill et al., 2010b). In the near 
future, it will be important to extend investigations in disease models to fully determine their 
potential as therapeutic agents in their own right or their use as a structural basis for rational 
drug development, and then progress into clinical trials. 
 
4.2 Phytocannabinoids in the treatment of CNS neurodegenerative diseases 
4.2.1 Historical background 
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Neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are 
characterised by a progressive loss of viable, functional neurons within one or more regions of 
the CNS, leading to specific deficits that increase in severity as the disorder progresses. A strong 
neuroinflammatory response is also observed in AD and PD (Lee et al., 2010; Qian et al., 2010) 
and is characterised by activation of microglia and the release of inflammatory agents. This 
inflammatory response is now itself considered a significant pathological cause of 
neurodegeneration. Additionally, the autoimmune CNS disease MS is also understood to have a 
neurodegenerative element crucial to the pathology of the disease which worsens in parallel with 
the development of symptoms (Stadelmann et al., 2011). Thus, although AD, PD and MS have 
distinct aetiologies, they all exhibit both neurodegeneration and inflammation. As described 
above, cannabis has been used for many thousands of years in the treatment of a wide range of 
disorders and illnesses; the first historical uses of cannabis in a wide range of neurological 
disorders are comprehensively discussed in Russo (2007). Neuroprotective effects of cannabis 
have been suggested as early as ~1200 A.D. in India (Shou-Zhong, 1997) and more recently in 
the West when treating dementia (Reynolds, 1868). Prolonged use of an Indian hemp preparation 
was also reported to "quiet the tremor for a time" for a patient with Parkinson's in 1888 by Sir 
William Gowers (Gowers, 1888). More recently, a survey sent to PD sufferers treated at the 
Prague Movement Disorder Centre reported a benefit of cannabis in nearly half of respondents 
(Venderova et al., 2004). These reports, alloyed with the anti-inflammatory, antioxidant and 
immunomodulatory properties of several pCBs (Section 3.3) have led to preclinical research in 
animal models of neurodegenerative diseases and, in some cases, limited human trials in AD, 
HD and PD, which are outlined below. 
Whilst a significant clinical benefit of pCBs for many neurodegenerative disorders has 
yet to fully manifest, the link between cannabis and the relief of MS symptoms, primarily 
spasticity, has a richer history. The first reference to the muscle relaxant properties of cannabis 
may have been as early as the 9
th
 century A.D. (Russo, 2007), with further reports by 
O'Shaughnessy in the 19
th
 century (O'Shaughnessy, 1840). Small-scale human studies into the 
beneficial effect of cannabis and 
9
-THC on MS symptoms between 1983 and 2002 (for review 
see Rog, 2010), as well as anecdotal reports of benefits and a report from the British Medical 
Association (1997), prompted the British government to call for a large-scale clinical 
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investigation of the effects of cannabis on MS (House of Lords, 1998). Additionally, changes in 
the ECS, particularly CB1 receptor expression, have been shown to occur in human and 
experimental Parkinsonism (Silverdale et al., 2001; Hurley et al., 2003; Walsh et al., 2010) and 
Huntington‟s disease (HD) (Blazquez et al., 2011), suggesting CB1 receptors may be a target for 
drug interventions in these diseases. In the following section we discuss the extant, largely 
clinical, data regarding the effect of SCEs on MS symptoms and associated preclinical research. 
Following this, the preclinical research on pCB effects in animal models of AD, PD and HD is 
summarised, as are the limited number of relevant human studies.  
 
4.2.2 Phytocannabinoids in multiple sclerosis (MS) 
MS is a chronic, progressive disease that is most frequently diagnosed in young adults. The 
majority of patients experience acute attacks followed by months or even years of remission, 
with attacks becoming progressively more severe in later life (Compston & Coles, 2008). The 
pathological basis of MS is the formation of inflammatory, demyelinating lesions in the CNS 
with resultant axonal loss, neuronal death and sclerotic plaques result (for review, see 
Stadelmann et al., 2011). Preclinical research from animal models of MS has suggested a 
potential role for pCBs in the attenuation of inflammation and the protection of neurons at risk of 
damage. As early as 1989, 
9
-THC was reported to delay or prevent signs of symptom onset in 
the experimental allergic encephalomyelitis model of MS in mice, as well as increasing survival 
rates and decreasing neuroinflammation (Lyman et al., 1989). Recent work has indicated that 
CB1 and CB2 agonists, including 
9
-THC, can limit symptoms, relapses, axonal loss and 
neuroinflammation in rodent models of MS (Arevalo-Martin et al., 2003; Croxford & Miller, 
2003; Docagne et al., 2007; Maresz et al., 2007; Hasseldam & Johansen, 2010). 
9
-THC (10 
mg/kg) has also been reported to control spasticity in the chronic relapsing experimental allergic 
encephalomyelitis mouse model of MS via a CB1-dependent mechanism (Baker et al., 2000). 
Clinical investigation of SCEs in the treatment of MS symptoms have focussed on 
extracts with 
9
-THC and CBD as their primary active ingredients; other pCB/plant matter is 
minimised at <10%. The reader is directed to two additional reviews by Lakhan & Rowland 
(2009) and Rog (2010) for a more detailed description of these studies. The cannabinoids in MS 
study (CAMS) investigated the effects of dronabinol (Marinol, a synthetic 
9
-THC) and 
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Cannador (2.5:1.25mg 
9
-THC:CBD SCE delivered in capsule). In a randomised, large-scale, 
placebo-controlled trial, neither dronabinol nor SCE (maximum 
9
-THC dose 25mg/day) 
significant affected objective (Ashworth Scale) measures of spasticity, but strong positive 
outcomes were observed for both drugs against control as assessed by patient-reported measures 
of spasticity and pain (Zajicek et al., 2003). A one-year follow up in which patients remained on 
their treatment suggested that the patient-reported benefit is maintained (Zajicek et al., 2005). 
The pattern of strong significant improvements in patient-reported measures of spasticity 
combined with changes in objective spasticity measures in favour of the SCE, but not 
significantly so, is common for SCE clinical studies; however, a significant improvement in 
Ashworth Scale scores was reported by Vaney et al. (2004) after treatment of 57 patients for two 
weeks with a 
9
-THC/CBD SCE (maximum dose 30.8 mg/10.8 mg 
9
-THC/CBD per day).  
Sativex (2.7:2.5 mg/100 l spray marketed as Nabiximols) is delivered as an oromucosal 
spray, the benefit of which is a faster plateau of plasma concentrations compared to the oral route 
(GW Pharmaceuticals, 2001). Sativex is now licenced in a number of countries for adjunctive 
treatment of spasticity in MS, as well as for neuropathic pain in Canada. Wade and co-workers 
measured the effect of Sativex (<120 mg/day) on a variety of MS symptoms, and found that 
patient-reported (visual analogue scale) spasticity scores were significantly lowered by Sativex 
(Wade et al., 2004). A long-term open label extension found that Sativex maintained this 
beneficial effect (Wade et al., 2006). Collin et al. (2007) also reported significant improvements 
in spasticity as measured by a patient-reported daily numerical rating scale (NRS) score of 
spasticity, the primary endpoint. Secondary outcomes (including Ashworth Scale outcomes) 
were non-significantly in favour of Sativex (up to 48 doses/day Sativex). Most recently, a large-
scale trial used an initial four-week single-blind Sativex regimen to identify a patient population 
that responded well to Sativex (maximum 12 sprays/day; Novotna et al., 2011). Around 40% of 
patients had spasticity NRS results that were improved by ≥20% in the first four weeks; these 
responders were randomised into a double-blind, placebo-controlled study (12 weeks), and 
Sativex was shown to significantly improved spasticity NRS scores and several other secondary 
outcomes, including spasm frequency and sleep disturbances.  
Sativex, CBD and dronabinol were each found to be effective in treating MS-related and 
neuropathic pain in a recent meta-analysis (Iskedjian et al., 2007). Additionally, one double-
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blind, randomised placebo-controlled five-week trial reported a significant effect of Sativex in 
alleviating MS-related pain (maximum 48 sprays/day; Rog et al., 2005). This effect was 
maintained without signs of tolerance in an open-label, uncontrolled two year extension that 
recruited participants from the previous trial (Rog et al., 2007). Further investigation into 
whether pCBs can alter the progression of MS in addition to effectively ameliorating symptoms 
could provide further justification for cannabis-based treatments for this disease, such 
investigations are currently in progress in the CUPID (Cannabinoid Use in Progressive 
Inflammatory Brain Disease) long-term (three year) study in which 493 MS patients are 
randomised to a placebo or 
9
-THC treatment group (Clinical Neurology Research Group, 
2009).  
 
4.2.3 Phytocannabinoids in Alzheimer‟s disease (AD) 
AD is the most common form of dementia, with age being a significant risk factor. AD is 
associated with the formation of neurofibrillary tangles, senile plaques and cortical atrophy (Perl, 
2010). At present, there is limited preclinical data regarding the effects of pCBs in animal 
models of AD. A single in vitro study has suggested that 
9
-THC competitively inhibits 
acetylcholinesterase (Eubanks et al., 2006), a therapeutic strategy that is approved to treat mild 
to moderate AD (Ellis, 2005). Iuvone and colleagues have shown that CBD (≥0.1 M) decreases 
levels of -amyloid-associated reactive oxygen species and lipid peroxidation in PC12 cells and 
in vivo (Iuvone et al., 2004). Extending these studies, Esposito et al. (2006) demonstrated that 
CBD (≥1 M) attenuated a -amyloid-induced increase in iNOS, also decreasing levels of p38 
MAP kinase and NF- B, both of which are involved in the response to oxidative stress. The 
same group showed that CBD (2.5 and 10 mg/kg) attenuated the -amyloid inflammatory 
response in vivo by limiting iNOS and IL-1  expression (Esposito et al., 2007). More recently, 
Martin-Moreno et al. (2011) have shown that CBD (20 mg/kg) can limit microglial activation in 
in vitro and in vivo models of AD.  
In line with limited preclinical data available at present, there is no published data 
describing clinical effects of pCBs on human AD (Krishnan et al., 2009), with the exception of a 
single, small (six subject), open-label, non-placebo controlled study which reported that synthetic 
9
-THC (dronabinol; 2.5 mg/day) alleviates night-time agitation in patients with AD or vascular 
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dementia (Walther et al., 2006). Reports of CBD effects on in vitro and preclinical in vivo 
models of AD, allied with the high tolerability of CBD in humans, suggest that further 
investigation of therapeutic potential is merited in AD, particularly given that seizures are a 
common symptom of AD (Leppik & Birnbaum, 2010) that could also benefit from the 
anticonvulsant effects of CBD described previously. 
 
4.2.4 Phytocannabinoids in Parkinson‟s disease (PD) 
PD is primarily a movement disorder characterised by bradykinesia, tremor at rest and rigidity. 
The death of nigral dopaminergic neurons that innervate the striatum and modulate motor 
behaviour is responsible for these motor symptoms, resulting in a loss of tyrosine hydroxylase 
positive (TH+) neurons in the substantia nigra and reduced dopamine levels in the striatum. 
Neuropsychiatric symptoms are also common, as are sleep disturbances (for review, see Hindle, 
2010). The effects of CB receptor ligands and pCBs on neuronal death, motor symptoms and 
inflammation have been widely investigated in preclinical animal models of Parkinsonism and 
there is evidence that pCBs can provide symptomatic relief and neuroprotection from 
experimentally-induced Parkinsonism.  
Evidence for the efficacy of 
9
-THC in ameliorating motor symptoms in PD models is 
mixed. Meschler et al. (2001) found that 
9
-THC (>1 mg/kg) exacerbated of Parkinson-like 
bradykinesia induced by administration of MPTP, a toxin that kills dopaminergic neurons, into 
the substantia nigra in cynomolgus monkeys. By contrast, 
9
-THC (~4mg/kg) caused 
improvement in both activity and hand-eye coordination in MPTP-treated marmosets (van Vliet 
et al., 2008). The contrasting results could be explained by the use of different monkey species, 
MPTP- and 
9
-THC-dosing regimens, and clinical measures of Parkinsonism. In MPTP-treated 
marmosets, CB receptor agonism by the synthetic 
9
-THC analogue (nabilone, ≥0.1mg/kg) has 
been reported to decrease L-DOPA-induced dyskinesias (Fox et al., 2002). Rats that received 
daily treatment with 
9
-THC or CBD (both 3 mg/kg) for 2 weeks post-lesion had significantly 
higher levels of TH mRNA and dopamine ipsilateral to the lesion compared to vehicle-treated 
animals in the 6-hydroxydopamine (6-OHDA) model of PD (Lastres-Becker et al., 2005). This 
neuroprotective effect is likely to be CB1-independent, due instead to the antioxidant capacity of 
pCBs (Garcia-Arencibia et al., 2007).  
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9
-THCV has an attractive range of properties in relation to PD, 
9
-THCV is likely to 
share the neuroprotective antioxidant properties possessed by other pCBs and can act as a CB2 
agonist in vivo (Bolognini et al., 2010; Pertwee, 2008), and can therefore affect microglial 
activation; additionally, 
9
-THCV is a CB1 antagonist, and the CB1 antagonist SR141716A (0.1 
mg/kg) has been shown to ameliorate motor symptoms in animal models of Parkinsonism 
(Gonzalez et al., 2006; Garcia-Arencibia et al., 2008; Kelsey et al., 2009). Acute administration 
of 
9
-THCV (2 mg/kg) has recently been shown to improve motor performance in the 6-OHDA 
model of Parkinsonism in rat (Garcia et al., 2011); 
9
-THCV increased striatal glutamate, but not 
dopamine, levels in a manner consistent with CB1 antagonism. In the same study, chronic 
9
-
THCV (2 mg/kg) administration partially protected TH+ cells from 6-OHDA-induced death, 
attenuated microglial activation and also exerted a significant neuroprotective effect on nigral 
TH+ neurons in the LPS model of PD in mice. The LPS model exhibits greater CB2 up-
regulation than the 6-OHDA model; the effectiveness of a CB2-specific agonist and the 
exacerbation Parkinsonism in mice lacking CB2 receptors suggest 
9
-THCV may be 
neuroprotective in a CB2-dependent manner in this model (Garcia et al., 2011).  
Investigation of the effects of cannabis and pCBs in human PD is limited. Small-scale 
human studies have investigated the effect of nabilone (Sieradzan et al., 2001) and Cannador 
(Carroll et al., 2004) on dyskinesias caused by the most common PD treatment, L-DOPA. Whilst 
nabilone (0.03 mg/kg) was reported to significantly improve dyskinesias in pilot trial in 7 
patients as assessed by the Rush Dyskinesia Scale (Sieradzan et al., 2001), two patients withdrew 
due to adverse side-effects. Cannador (maximum 
9
-THC dose of 0.17 mg/kg/day) had no effect 
on dyskinesia as assessed by several parameters, although it was well-tolerated, possibly due to 
an earlier dose escalation study to determine suitable dosages (Carroll et al., 2004). CBD alone 
(≤400 mg/day) has been reported as effective in the treatment of PD-associated psychosis over 
four weeks of treatment in six consecutive patients presenting with three or more months history 
of psychosis (Zuardi et al., 2009), consistent with findings that CBD is an anti-psychotic (Zuardi 
et al., 2006). However, a study primarily concerned with dystonia found that CBD (>300 
mg/day) aggravated Parkinsonism in two patients (Consroe et al., 1986). The Venderova et al. 
(2004) survey referred to previously represents the most promising finding regarding PD and 
human use of cannabis. A quarter of respondents reported cannabis (predominantly oral, not 
 24 
 
smoked) use for PD symptom relief. Nearly half (45.9%) described a mild or substantial 
alleviation of symptoms above that provided by their prescribed treatment. Of these individuals, 
significant numbers reported improvements in resting tremor (30.6%) and bradykinesia (44.7%), 
14.1% also reported alleviation of L-dopa-induced dyskinesia. 4.7% reported a worsening in 
symptoms (Venderova et al., 2004). This study, whilst a simple survey, indicates that further 
work is merited. 
The use of pCBs in the treatment of various facets of preclinical experimentally-induced 
Parkinsonism appears promising. Specifically, although at an early stage of investigation, the 
combined properties of 
9
-THCV (antioxidant, CB1 receptor antagonist, CB2 receptor agonist) 
hold promise in combating neurodegenerative, immunological and motor function symptoms of 
PD; the anti-inflammatory and antioxidant properties of CBD are also attractive. The current 
clinical evidence is very limited in scope, and therefore whilst findings are not uniformly 
positive, more extensive human studies are required to ascertain whether preclinical promise can 
be translated into treatments for this age-dependent, poorly-controlled disorder. 
 
4.2.5 Phytocannabinoids in Huntington‟s disease (HD) 
HD is a movement disorder that also causes cognitive and behavioural changes (for review, see 
Kumar et al., 2010). An autosomal dominant mutation of the Huntingtin protein is responsible 
for HD, causing neuronal death in the striatum and other areas of the brain, with spiny 
GABAergic neurons most affected (Gil & Rego, 2008). HD is also associated with a loss of CB1 
receptors (Blazquez et al., 2011). CBD and 
9
-THC (both 5mg/kg) were neuroprotective in the 
3-nitropropionic acid-induced striatal lesion HD model (Lastres-Becker et al., 2004; Sagredo et 
al., 2007); the effects of 
9
-THC were most likely mediated by CB1 receptors, whilst the effects 
of CBD were proposed to be due to antioxidant properties. However, daily treatment with 
9
-
THC (10 mg/kg over 8 weeks) reportedly had no effect on motor deterioration in a mouse 
transgenic model of HD (Dowie et al., 2010). 
A small clinical trial following daily CBD (300-600 mg) treatment demonstrated an 
improvement in HD symptoms in 1 of 4 participants (Sandyk et al., 1989); however, a double-
blind randomised placebo-controlled crossover trial in 15 HD patients showed no significant 
effect of CBD (10 mg/kg/day, 6 weeks) on chorea severity (Consroe et al., 1991). More recently, 
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a randomised, double-blind crossover placebo-controlled trial with 37 patients investigating the 
effects of the synthetic 
9
-THC analogue nabilone (1-2 mg) showed no effect on the primary 
outcome (the Unified Huntington's Disease Rating Scale), but some evidence of improvement in 
chorea and neuropsychiatric outcomes (Curtis et al., 2009). As with other disorders, further 
clinical research is required into the effects of pCBs in HD to elucidate the potential benefits. 
The recent finding that loss of striatal CB1 receptor expression may be an important factor in the 
pathogenesis of HD (Blazquez et al., 2011) indicates that the ECS system is a rational target for 
HD treatment, which may include pCB-based medicines. 
 
4.2.6 Summary 
The ability of a combination of 
9
-THC and CBD to decrease symptoms associated with MS has 
led to the introduction of Sativex, the first licensed pCB drug. Moreover, there is increasing 
preclinical evidence that indicates pCBs may also be of benefit in treating the development of 
several neurodegenerative disorders; in particular, CBD‟s ability to modulate immune cell 
activity in the CNS and limit oxidative stress is promising and confers strong neuroprotective 
capacity. However, it should be noted that previously proposed, putative treatments for 
neurodegenerative diseases that exploit antioxidant and anti-inflammatory strategies have, in 
many cases, met with limited clinical success (Dumont & Beal, 2011; Whitton, 2010). Apart 
from the positive data gathered in the past decade on the effects of SCEs on MS symptoms, at 
present there is very little human data available on pCB effects in neurogdegenerative disorders. 
Thus, coordinated clinical trials investigating the effect of pCBs on both disease progression and 
symptom control for a range of neurodegenerative disorders are required to determine if and how 
pCBs can benefit patients with AD, HD and PD, all of which have a significant unmet clinical 
need. Encouragingly, most pCB-based treatments investigated to date, independent of the target 
disorder, appear to be well-tolerated, a promising sign for further clinical studies. Whilst most 
research has been performed on CBD, other pCBs share antioxidant capacity and may be more 
suited to specific diseases states. For example, 
9
-THCV effects in models of PD appear to limit 
both neuronal cell death and the associated immune response whilst decreasing signs of 
bradykinesia. 
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4.3. Phytocannabinoids in affective disorders 
In this section, we consider affective disorders; it is notable that pCBs also have effects in non-
affective psychosis disorders, including schizophrenia (Hallak et al., 2011), however, such 
actions are not considered here. 
 
4.3.1 Historical background 
Cannabis has been used as a treatment for mood disorders for several thousand years, with well-
documented use as a hypnotic and tranquilizer in the treatment of anxiety, mania, and hysteria 
(Mechoulam et al., 1970). Use of the plant continued into the early part of the 20
th
 Century, 
where extracts have been used for their sedative and hypnotic properties to treat insomnia, 
melancholy, mania, and delirium (Russo & Guy, 2006). However, a decline and eventual 
cessation of cannabis use in psychiatry occurred over the last 100 years due to the development 
of new and more selective hypnotic and sedative drugs with well-characterised modes of action, 
alongside prohibition of use of the plant. However, the recent isolation and identification of 
pCBs with little or no psychoactivity is of particular relevance here and gives rise to the prospect 
of new therapeutic agents which may be used for the treatment of the affective disorders.  
 
4.3.2 Phytocannabinoids in anxiety 
Cannabis use has been associated with a high prevalence of anxiety; however, individual pCBs 
have been shown to possess anxiolytic properties (Crippa et al., 2009; Crippa et al., 2011) and 
thus use of specific pCBs (or selected combinations thereof) may hold as yet unexploited, 
therapeutic potential in the treatment of anxiety disorders. 
There is evidence to suggest a significant comorbidity between cannabis use and 
prevalence of anxiety disorders. Reilly et al. (1998), using a structured interview in a rural area 
of Australia, found that 21% of long-term cannabis users reported high levels of anxiety, 
paranoia or depression. Similarly, Saban et al. (2010) investigating the relationship between 
substance misuse and psychopathology in high school students, reported a significant association 
between cannabis use and levels of anxiety. Furthermore, a recent study in Italian university 
students demonstrated a link between cannabis use and levels of anxiety which may, in turn, 
trigger risky and suicidal behaviour (Innamorati et al., 2008). In a study with 18-year-old New 
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Zealanders, it was reported that those who had smoked cannabis at least ten times between the 
ages of 15 and 16 had twice the prevalence of anxiety disorders compared to those who had 
never used the drug (Fergusson & Horwood, 1997). Likewise, in a study investigating emotion 
regulation and mental health problems, Dorard et al. (2008) found that more than half of the 
cannabis abusers reported comorbid diagnosis of CNS disorders, most commonly affecting mood 
and anxiety. 
By contrast, it has been suggested that subjects with high levels of anxiety and patients 
with anxiety disorders use cannabis as a form of “self-medication” to treat symptoms. In support, 
an elegant analysis of the US National Comorbidity Survey showed that a large proportion of 
subjects developed anxiety disorders prior to the onset of their first symptoms of cannabis 
dependence, implying that the subjects were self-administering cannabis as an anxiolytic 
medication (Agosti et al., 2002). In line with this hypothesis, Buckner & Schmidt (2008) 
examined the temporal sequencing between the onset of seasonal affective disorder (SAD), 
alcohol misuse and cannabis dependence. Using a sample of participants from the Oregon 
Adolescent Depression Project, it was reported that SAD was an independent risk factor for the 
subsequent onset of cannabis dependence (Buckner & Schmidt, 2008). Overall, whilst cannabis 
may be anxiogenic in otherwise healthy cohorts, there are clear indications of anxiolytic effects 
in sufferers of anxiety disorders 
The anxiolytic effects of CBD have been thoroughly investigated in preclinical models. 
The earliest reported study by Zuardi & Karniol (1983) showed that purified CBD (10 mg/kg) 
significantly decreased conditioned emotional responses to a stimulus in rats. Resstel & 
colleagues used a restraint stress paradigm in rats, which raises blood pressure and increases 
heart rate indicative of human anxiety behaviour, to demonstrate that CBD (1- 20 mg/kg) 
decreased acute autonomic responses (Resstel et al., 2009). Similarly, Guimaraes et al. (1990) 
showed that mice treated with 2.5-10 mg/kg (but not 20.0 mg/kg) CBD spent a greater amount of 
time in the open arm of an elevated plus maze, an effect similar to that produced by the standard 
anxiolytic agent diazepam. The anxiolytic actions of CBD have also been demonstrated in the 
mouse model of social defeat (Pistovcakova et al., 2006), the Vogel conflict test (Moreira et al., 
2006), the conditioned fear paradigm (Resstel et al., 2006) and the contextual fear memory 
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extinction paradigm (Bitencourt et al., 2008). Taken together, the results from animal studies 
suggest that CBD has anxiolytic potential. 
Preclinical data have led to a number of studies investigating possible anxiolytic actions 
in healthy and clinical human populations. An early study using healthy volunteers subjected to a 
stressful public-speaking test (SPST) showed that CBD (300 mg) reduced the volunteer‟s 
subjective anxiety to levels comparable with the standard anxiolytic, diazepam (Zuardi et al., 
1993). A follow-up study by the same group (Crippa et al., 2004) used functional neuroimaging 
to demonstrate that CBD (400 mg) significantly decreased subjective anxiety; importantly, CBD 
also significant decreased regional cerebral blood flow (rCBF) in the left hippocampal and 
parahippocampal gyrus regions, indicative of an action on limbic and paralimbic brain areas. 
Later, Fusar-Poli et al. (2009) used functional magnetic resonance imaging to investigate neural 
correlates of the anxiolytic properties of CBD, demonstrating that CBD (600 mg) reduced 
amygdala, anterior cingulate cortical and posterior cingulate cortical activity in 15 healthy 
subjects subjected to a sequence of fearful facial stimuli. A recent study substantiated the role of 
CBD, whereby increases in anxiety induced by the SPST on subjects with SAD was reduced by 
CBD (600 mg) (Bergamaschi et al., 2011). In a clinical context, Crippa et al. (2011) investigated 
the effects of CBD treatment in 10 patients with generalised SAD; CBD (400 mg) significantly 
reduced subjective anxiety and led to reduced rCBF in left parahippocampal gyrus, hippocampus 
and inferior temporal gyrus, while increasing rCBF in right posterior cingulated gyrus. The 
authors suggest that CBD produces its anxiolytic actions due its effects on activity in limbic and 
paralimbic brain areas. To date, no studies have investigated the actions of other pCBs on 
anxiety, but it seems that CBD has promise as an anxiolytic agent. The description of both 
anxiogenic and anxiolytic actions of ingested cannabis also raise the possibility that individual 
pCBs have differential effects on anxiety; for example, anxiolytic CBD may oppose the 
anxiogenic effects of 
9
-THC (Zuardi et al., 1982); such a description would fit well with the 
general concept that CBD can usefully ameliorate unwanted 
9
-THC effects discussed 
previously. 
 
4.3.3 Phytocannabinoids in depression 
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Elevation in mood and reduction in levels of stress following recreational cannabis use have been 
documented anecdotally for many years (Skolnick et al., 2001). Indeed, a recent internet survey 
comparing individuals with differing levels of marijuana use showed that those who used 
marijuana daily and those who used marijuana once per week or less reported less depressed 
mood and more positive affect than non-users (Denson & Earleywine, 2006). However, a review 
of the literature also reveals that cannabis ingestion is associated with an increased incidence of 
bipolar disorders and depression (Jarvis et al., 2008; van Rossum et al., 2009). As a result of 
these bi-directional effects research has largely focussed on understanding the role of the ECS in 
the pathogenesis and treatment of depression, rather than an investigation of the potential 
therapeutic actions of pCBs (for a recent review see Parolaro et al., 2010). Here, we will restrict 
our discussion to studies that have investigated the actions of individual pCBs in depressive 
syndromes. 
The suggestion of a potential antidepressant role for Δ9-THC is widespread. In the early 
1980‟s the effects of Δ9-THC (2.5 and 10 mg/kg delivered by paced smoking of herbal 
cigarettes) showed increases in relaxation and decreases in subjective ratings of anxiety, tension 
and depression (Ashton et al., 1981). In a clinical setting, significant antidepressant actions of 
Δ9-THC treatment have been documented in patients suffering advanced cancer (Regelson et al., 
1976), MS (Martyn et al., 1995; Svendsen et al., 2004) or chronic pain (Notcutt et al., 1997; 
Wade et al., 2003). However, as suggested above, evidence in support of a cannabis 
antidepressant action is equivocal. An early study by Kotin et al. (1973) reported that in 8 
hospitalized patients with moderate to severe depression, Δ9-THC administered for up to 7 days 
failed to exhibit any significant antidepressant response; however, the small sample size, limited 
study duration and relative severity of symptoms may hinder a firm conclusion from this study. 
A comprehensive analysis of the potential antidepressant action of isolated pCBs has 
recently been reported by El-Alfy et al. (2010), where antidepressant actions of major pCBs were 
evaluated in the forced swim test (FST) model in mouse. Compounds that showed an anti-
depressant action in the FST were additionally tested in the tail suspension test (TST). Both the 
FST and TST are standard preclinical tests used to measure the effect of antidepressant drugs. 
Classically, the results of these tests have been interpreted such that the time spent immobile is 
considered a behavioural correlate of negative mood. Treatment with 2.5 mg/kg Δ9-THC (but not 
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1.25 or 5.0 mg/kg) produced a significant reduction in overall immobility time in both the FST 
and TST, consistent with an antidepressant action. Interestingly, similar reductions in time spent 
immobile in both the FST and TST were also seen with CBC. Here, 20 mg/kg CBC elicited 
decreased immobility time in the FST, whilst both 40 and 80 mg/kg CBC were effective in the 
TST. Finally, 200 mg/kg CBD decreased time spent immobile in the FST, but failed to show any 
further anti-depressant actions in the TST; treatment with Δ8-THC, CBG or CBN failed to elicit 
any antidepressant-like actions (El-Alfy et al., 2010). Only one other study has investigated the 
actions of CBG to alleviate depression, CBG (40-80 mg/kg) produced significant reductions in 
the time spent immobile in the TST, with comparable effects to a known anti-depressant dose of 
imipramine (Musty & Deyo, 2006). Work by the same authors has also demonstrated a potential 
anti-depressant role for CBC (greatest activity seen at 40 mg/kg) using the TST (Deyo & Musty, 
2003). 
Of the non-Δ9-THC pCBs, CBD appears to be the most thoroughly researched for its 
antidepressant actions. However, as highlighted by El-Alfy et al. (2010), results to-date have not 
always been consistent. Following the successful demonstration that CBD administration could 
reduce the behavioural consequences of restraint stress (Resstel et al., 2009), it was further 
shown that CBD (30, but not 3, 10 or 100 mg/kg doses) increased time spent swimming in the 
FST (Zanelati et al., 2010); interestingly, pre-treatment with a 5-HT1A receptor antagonist 
blocked CBD action. Finally, in a small-scale human trial, 2 patients suffering bipolar affective 
disorder and experiencing a manic episode failed to show any improvement in symptoms in 
response to CBD treatment for 25 days (initial oral dose of 600 mg/day rising to 1200 mg/day), 
although this may reflect a differing aetiology underlying positive and negative symptoms in 
bipolar disorder (Zuardi et al., 2010). 
 
4.3.4 Summary 
These data suggest that, in the future, individual pCBs may have important therapeutic 
advantages over the ingested cannabis used in earlier studies in the treatment of affective 
disorders. At present, CBD is the most likely pCB to be translated into clinical practice due to its 
non-psychoactivity, safety and tolerability. However, long-term, double-blind, placebo-
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controlled trials with subjects suffering from different affective disorders are still necessary and 
critical for this to be realised. 
 
4.4 Phytocannabinoids and feeding-related disorders  
In this section, we will explore the actions of the pCBs on food intake, a phenomenon that is 
intimately associated with modulation of feeding circuits in the hypothalamus by the eCB system, 
at present proposed to be principally due to an action on CB1 receptors (Pagotto et al., 2006; Di 
Marzo et al., 2009). Whilst a detailed description of brain reward circuitry and interactions with 
the eCB system is beyond the scope of this article, several authors have reviewed these aspects in 
detail (Cota et al., 2003; Kirkham, 2008). It is clear that food intake may activate eCBs to 
stimulate reward pathways to engender further feeding behaviour. CB1 receptor antagonists are 
well-known anti-obesity agents (Lee et al., 2009); however, obesity per se is not a solely CNS 
disease, rather, our discussion will be related to clinical conditions such as cachexia, anorexia 
and malnutrition, including the establishment of such conditions as a consequence of diseases 
such as AIDS, cancer and AD, diseases in which a disorder of appetite is a core feature. 
 
4.4.1 Historical background 
The appetite-stimulating, orexigenic properties of marijuana have been documented as far back 
as 300 A.D. (Chopra & Chopra, 1939). However, this seemingly well-substantiated phenomenon 
was previously only sparsely supported by empirical evidence, with few detailed human studies 
and even fewer well-controlled animal studies. In an early report, Hollister (1971) demonstrated 
that a single oral dose of marijuana (containing 0.35 mg/kg Δ9-THC) significantly increased 
intake of milkshakes in normal, unfasted volunteers. Foltin and colleagues showed that volunteer 
subjects given marijuana cigarettes (1.84 % w/w Δ9-THC) showed a markedly increase in food 
intake (1500 kcal), primarily attributable to an increase in snack food items (Foltin et al, 1986; 
Foltin et al., 1988).  
In animals, the first comprehensive dose-response analysis of Δ9-THC hyperphagia in 
rats was documented in the late 1990s (Williams et al., 1998); a range of Δ9-THC doses were 
administered orally to pre-satiated rats with significant hyperphagia seen at doses ≥0.5 mg/kg Δ9-
THC. Subsequently, this hyperphagia was shown to be mediated by CB1 receptors (Williams & 
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Kirkham, 2002b), and involved a marked reduction in latency to begin feeding (Williams & 
Kirkham, 2002a). Together these effects imply that the stimulation of feeding induced by ∆9-
THC may be linked to the appetitive phase of feeding, being associated with orienting an animal 
toward food and increasing the salience or reward value of food stimuli. The concept of 
cannabinoids influencing reward processes is well-established and has been supported by 
findings that blockade of CB1 receptors by SR141716A reduced sensitivity to the rewarding 
effects of electrical brain stimulation (Arnold et al., 2001; Deroche-Gamonet et al., 2001) and 
blocked the acquisition of drug- or food induced place preferences (Chaperon et al., 1998). 
Conversely, stimulation of CB1 receptors underlie the motivation to obtain and ingest palatable 
ingesta (Gallate & McGregor, 1999; Gallate et al., 1999; Higgs et al., 2003). Overall, current 
evidence suggests that animals work harder to obtain food after ∆9-THC treatment, and eat 
earlier and more frequently when food is freely available.  
At present, clinical interventions involving pCBs in syndromes affecting food 
consumption are dominated by use of ∆9-THC and synthetic analogues. Cachexia is 
characterised by metabolic changes associated with a severe loss of appetite (McGrath, 2002) 
and is a common feature of the later stages of diseases such as AIDS and metastatic cancer (Cat 
& Coleman, 1994; Inui, 2002). Thus, treatments aimed at stimulating appetite by enhancing the 
attractiveness and enjoyment of food should be beneficial in these circumstances. Sacks and 
colleagues found that treatment with dronabinol (5 mg, three times daily) had little effect on food 
intake, but greatly attenuated the reduction in daily energy intake produced by chemotherapy 
(Sacks et al., 1990). In the field of HIV-wasting syndrome, chronic daily dronabinol treatment 
(5-20 mg, orally for up to 20 weeks), caused a highly significant increase in appetite and mood 
ratings, with the majority of patients gaining weight over the course of treatment (Plasse et al., 
1991). Similarly, Beal et al. (1995) evaluated the long-term effects of ∆9-THC or placebo in 
patients with AIDS-related appetite and weight loss; dronabinol (2.5 mg, twice per day over 42 
days) administered to patients who had suffered progressive weight loss, experienced either 
stabilization of their body or a modest weight gain, accompanied by substantial increases in 
appetite.  
Wasting and loss of appetite are also important features of ageing and associated 
conditions such as dementia (Morris & Volicer, 2001; Hickson, 2006). It is therefore possible 
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that the appetite-stimulating properties of cannabinoids may be a useful tool in attempting to 
maintain proper nutrition in these populations. Dronabinol (5 mg per day over 6 weeks) 
produced significant weight gain, but not increases in energy intake, in food-refusing dementia 
patients (Volicer, 1997). Finally, a possible target for the application of cannabinoids to stimulate 
appetite and overcome food refusal may be in the treatment of anorexia nervosa, a psychiatric 
condition exemplified by self-starvation. Dronabinol has been used to successfully manage 
appetite in elderly patients suffering from anorexia and significant weight loss (Wilson et al., 
2007). By contrast, a study in 11 female patients with primary anorexia nervosa failed to show an 
effect of ∆9-THC on daily changes in weight and caloric intake versus an active diazepam 
placebo (Gross et al., 1983). However, it should be noted that the underlying psychopathology of 
anorexia is very complex, and involves significant psychological factors that are unrelated to any 
dysfunction in the normal physiological mechanisms controlling eating. 
 
4.4.2 Phytocannabinoid standardised cannabis extracts (SCEs) in feeding-related disorders 
Despite the evidence of Δ9-THC stimulatory effect on feeding and appetite detailed above, 
relatively few studies have investigated the contribution of non-Δ9-THC pCBs to the feeding 
effects of cannabis. However, recent work has demonstrated that a range of pCBs may have 
significant effects on feeding patterns (reviewed in Farrimond et al., 2011). In an initial study, 
the effects of purified Δ9-THC, synthetic Δ9-THC and Δ9-THC SCEs (which also contain an 
array of non-Δ9-THC pCBs) were compared (Farrimond et al., 2010a). Importantly, all 
treatments were matched to a range of Δ9-THC doses known to induce hyperphagia. Using 
standardised pre-feed paradigm (Williams et al., 1998), Δ9-THC SCE showed significantly lower 
hyperphagia in comparison to the synthetic and purified Δ9-THC doses; these data suggested that 
the combination of pCBs (and, potentially, non-pCB components) in the SCE attenuated the 
hyperphagic effects of Δ9-THC. In a follow-up study (Farrimond et al, 2010b), SCEs containing 
concentrations of Δ9-THC between two- and ten-fold lower than those previously demonstrated 
to induce hyperphagia, caused pre-satiated rats to significantly increase chow intake by reducing 
their latency to the first contact with food. These effects on feeding replicated those previously 
seen with much higher concentrations of pure Δ9-THC (Williams et al., 1998; Farrimond et al., 
2010a) and indicate that cannabis compounds other than Δ9-THC may also have the ability to 
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stimulate appetite, effects that were concealed when a higher concentration of Δ9-THC was 
present in the extract. It is clear from the data presented above (Farrimond et al., 2010a; 
Farrimond et al., 2010b) that the precise composition of an SCE is critical in determining the 
action on feeding, and that individual pCBs may antagonise the appetite-stimulating actions of 
Δ9-THC, whilst others may have appetite-stimulating properties themselves. Finally here, the 
action of two SCEs, one of these containing 67% ∆9-THC, the other a ∆9-THC-free SCE have 
been investigated; all remaining pCBs in the SCE were kept constant (CBD: 0.3%; CBG: 1.7%; 
CBC: 1.6%; Δ9-THCV: 0.9%; THCA: 0.3%; CBN: 1.5%; and sesame oil vehicle; total mixture 
dose range: 0.5 - 4.0 mg/kg) (personal communication, J Farrimond). Administration of both ∆9-
THC-free and 67%-∆9-THC SCEs induced highly significant dose-dependent increases in food 
consumption in the first hour after food was returned to the animals. This effect was attributed to 
highly significant reductions in the latency to the onset of feeding produced by both SCEs. 
However, some differences between the extracts were evident when considering other meal 
pattern parameters; most significantly, the 67% ∆9-THC SCE significantly increase the duration 
of the first meal, whilst the ∆9-THC-free SCE failed to induce any significant effect. This finding 
echoes those of previous studies (Farrimond et al., 2010b), further implicating non-Δ9-THC 
pCBs in the appetitive actions of feeding only. 
Despite these promising findings, only one single clinical trial has been undertaken to 
investigate the effects of an SCE on appetite and feeding. Strasser et al. (2006) compared the 
effects of Cannador (2.5 mg THC and 1 mg CBD), ∆9-THC (2.5 mg) and placebo on appetite and 
quality of life in patients with cancer-related anorexia-cachexia syndrome (CACS). Here, adult 
patients suffering significant weight loss were treated twice daily for 6 weeks with measures of 
appetite, mood, and nausea monitored daily. Results showed no significant differences between 
the three treatments, with increased appetite ratings of 73%, 58%, and 69% for patients receiving 
Cannador, THC, or placebo, respectively. 
 
4.4.3 Individual phytocannabinoids in feeding-related disorders 
Animal data presented to date strongly indicate that the non-Δ9-THC pCBs present in the SCEs 
produce significantly effects on the appetitive, but not consummatory, aspects of feeding 
behavior. Thus, determination of the effects of individual pCBs are clearly warranted; however, 
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prior to 2009 there were few studies investigating the actions of individual non-Δ9-THC pCB on 
feeding, with the majority of these studies being either unreplicated or even contradictory. In all 
cases, no detailed analyses of changes to feeding microstructure had been undertaken, which 
necessarily limits the interpretation of these findings. In 1976, Sofia and Knobloch examined the 
acute effects of CBN and CBD (both 50 mg/kg) on food and sucrose consumption. In this 
paradigm, animals were pre-trained to consume their total daily food intake during a 6 hour 
feeding period; water, 5% sucrose or 20% sucrose solutions were also available during this 
period. Both CBN and CBD significantly reduced food intake, effects which persisted for 4-5 
days post-drug administration (Sofia & Knobloch, 1976). CBN and CBD produced similar 
reductions in sucrose intake, which returned to pre-baseline levels by day 3-4 post-drug 
administration. The authors interpreted these findings as suggestive that CBN and CBD 
produced a preference for sweet calories. It should also be noted that the Sofia & Knobloch 
(1976) study used doses of CBN and CBD between 200 and 1500 times greater than the 
concentrations of these compounds used in other studies that have suggested that non-Δ9-THC 
pCB stimulate feeding (Farrimond et al., 2010a; Farrimond et al., 2010b). Wiley et al. (2005) 
showed that CBD (3-100 mg/kg) failed to significantly alter food intake in mice; yet it should be 
noted that doses of 3 and 10 mg/kg CBD showed a non-significant trend towards an increase in 
intake suggesting that CBD may be worthy of further investigation. However, a recent study by 
Scopinho et al. (2011) further demonstrated that CBD (1, 10 or 20 mg/kg) failed to alter feeding 
and failed to replicate the non-significant trend towards an increase in feeding at low doses. CBD 
(2.5 and 5 mg/kg/day for 14 days) has been reported to produce significant decreases in body 
weight in rats, although no measures of food intake were taken (Ignatowska-Jankowska et al. 
2011); interestingly, CBD action was sensitive to co-administration of the CB2 receptor selective 
antagonist, AM630, suggesting a CB2 receptor mechanism may be critical to the action of CBD 
on body weight.  
In general, there is a broad literature implicating CB1 receptor antagonists as potential 
anti-obesity agents; however, the recent failure of rimonabant has highlighted the need to 
develop safer alternatives (Lee et al., 2009; Izzo et al., 2009). In this regard, Riedel et al. (2009) 
have investigated the feeding effects of Δ9-THCV (3, 10 and 30 mg/kg) and a Δ9-THCV SCE 
(containing between 0.1 and 0.3 mg/kg Δ9-THCV). All doses of Δ9-THCV significantly reduced 
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food intake during the 12 h following treatment, whereas Δ9-THCV SCEs did not affect 
consumption. This study confirms that purified Δ9-THCV can reduce food intake in mice, which 
is worthy of further investigation. In particular, future work should investigate effects of purified 
Δ9-THCV and Δ9-THCV SCE using conditions which would be expected to maximise food 
intake (e.g. during the dark phase of the light:dark cycle or following periods of deprivation), 
thus ensuring high baseline food intake, maximizing the ability to detect any Δ9-THCV-induced 
decreases in food intake.  
 
4.4.4 Summary 
The association between the effects of exogenous CBs and appetite gave a strong lead in 
suggesting possible physiological roles for the ECS in feeding-related diseases. Indeed, Δ9-THC 
induces a degree of over-eating that far exceeds that produced by most other hyperphagic 
pharmacological manipulations. Crucially, the behavioural adjustments induced by exogenous 
CBs suggest that these compounds are involved in the processes which drive us to eat. Animals 
work harder to obtain food after CB1 stimulation, and eat earlier and more frequently when food 
is freely available. CB1 receptor agonists thus seem to actively provoke feeding, rather than 
merely prolonging eating that has been initiated through other mechanisms. More recent data has 
additionally shown a role for some non-Δ9-THC pCBs in the stimulation of appetite, however, no 
studies have clearly delineated the individual pCB which may underlie these appetite-stimulating 
actions. Thus, further studies in animal models and humans are needed to confirm the ability of 
individual pCBs to alter food intake, and to clarify the mechanisms of action underlying these 
effects, such initiatives may lead to the development of novel therapeutic strategies for the 
treatment not only of feeding disorders themselves, but also disorders arising as a symptom of 
other CNS diseases. 
 
5. Conclusions 
The demonstration that Cannabis sativa contains numerous pCBs in addition to the major 
psychoactive 
9
-THC component provides the impetus to support a solid body of preclinical 
studies focussing on therapeutic development of non-
9
-THC pCBs. Work in animal models of 
diseases is now being extended to an increasing number of clinical trials in human CNS 
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disease. The latter, in particular, has been fuelled by the introduction of the first SCE- and, by 
extension, pCB-, based medicine, Sativex. As well as providing a useful proof-of-concept, the 
introduction of Sativex may serve to lower the barriers to the perceived societal difficulties 
associated with cannabis-based medicines. In general, where 
9
-THC has been shown to be an 
effective treatment in animal models or clinically, the adverse side effects of CB1 agonism need 
to be weighed against the clinical benefit to patients; however, the combination of 
9
-THC and 
CBD into an SCE yields a medicine that is well-tolerated in the clinic, suggesting that the 
presence of 
9
-THC does not necessarily preclude the development of medicines suitable for 
widespread use.  
Whilst, generally still in their infancy, clinical data for effects of individual (or mixed) 
non-
9
-THC pCBs may be usefully extended to trials for feeding-related disorders, 
neurodegenerative diseases, affective disorders and epilepsy, amongst others. This review has 
highlighted CBD, as a compound with a multi-modal mechanism of action, with clear 
therapeutic potential in a number of these areas, befitting its status as the second most prevalent 
pCB in cannabis (Lerner, 1963). In general, whilst it can be seen that large doses of CBD can 
be tolerated in humans, it is worth pointing out that formulation of CBD (or other pCBs), for 
example with lipid vehicles or dispersing surfactants, during potential drug development could 
substantially increase bioavailability. It is also apparent that other pCBs, such as 
9
-THCV and 
CBG, may have a similar therapeutic potential, but that further preclinical work is needed to 
justify human trials. It is also clear that non-
9
-THC pCBs act at a wide range of molecular 
targets and may possess useful additional properties, such as anti-oxidant capacity, to support 
their pharmacological profile. A recurring issue is a pharmacological relevance of some of the 
pCB actions described herein; in this regard, pCBs typically exhibit functional responses with 
low micromolar potencies. A caveat here is that due to their high lipophilicity, for studies 
conducted in, for example, brain slice preparations, pCBs may partition into lipid membranes 
leading to underestimations of effective potency (discussed in Ma et al., 2008; see also Brown 
et al., 2004). Importantly, despite the relatively high concentrations required at some targets, 
pCBs such as 
9
-THCV and CBD are known to penetrate the blood–brain barrier well, with no 
major toxicity, genotoxicity, or mutagenicity (Hill et al., 2010a; Jones et al., 2010). Based on 
measurements of CSF levels in rat, we have calculated that 100 mg/kg CBD doses i.p. reach 
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CNS concentrations of ~18 M which suggests that low micromolar potencies can have 
functional relevance. In this regard, CBD doses as high as 1200 mg have been safely tolerated 
in human trials (Trembly & Sherman, 1990; see Table 1). Thus, the future of pCBs as safe and 
efficacious agents to combat CNS disease holds great pharmacological and therapeutic 
promise. 
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Figure legends 
 
Figure 1. Biosynthesis of major phytocannabinoids.  
 
Figure 2. Effect of phytocannabinoids on SR141716A binding in mouse cerebellum membranes. 
Competition binding assays for phytocannabinoids in comparison to standard synthetic CB1 
ligands against 1 nM [
3
H]SR141716A. B) 
9
-THCV has micromolar affinity and CBD and CBG 
have millimolar affinity for CB1 receptors. 
 
Figure 3. Effect of 
9
-THCV in mouse cerebellar brain slices. A) In patch clamp recording from 
IN-PC synapses, 
9
-THCV(58 M) increased frequency of miniature inhibitory postsynaptic 
currents and blocked agonist effects of WIN55,212-2 (WIN55; 5 M). B) In MEA recording 
from cerebellar slices (i), WIN55 (5 M)-induced increases in PC spike firing were significantly 
reversed by 
9
-THCV (5-40 M); * p<0.05 (Mann-Whitney U-test) 
 
Figure 4. CBD has a multi-modal action. Scheme showing some identified molecular targets and 
potential modes of actions for CBD in central neurons. 
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Table1: Summary of human case studies and clinical trials employing cannabinoids or 
cannabis in which a pro- or anti-convulsant effect was observed. The limited nature of some 
sources occasionally render information regarding study design, dosage routes, compound purity 
and origin unavailable. Extant and pertinent information has been included below. 
Report 
type 
Study 
drug 
Pro- or anti-  
convulsant  
Primary outcome Reference Notes 
Clinical 
trial 
9
-THC 
Anti-
convulsant 
„severe anticonvulsant 
resistant grand mal 
epilepsy controlled‟ in 2/5 
children; no change to 3/5 
children. 
Davis & 
Ramsey 
(1949) 
9
-THC administered to 5 
institutionalised children, 
previously unresponsive to 
phenobarbital and phenytoin.   
Case 
study 
Smoked 
cannabis  
Anti-
convulsant 
Full control of seizures 
Consroe et al. 
(1975) 
Isolated report of one adult using 
phenytoin and phenobarbital who 
only achieved full seizure control 
when also using smoked cannabis. 
Seizures returned when phenytoin 
and phenobarbital were withdrawn 
and only cannabis smoked. 
Clinical 
trial 
Oral 
CBD 
(≤300 
mg per 
day) 
Anti-
convulsant 
4/8 CBD treated patients 
with full seizure control, 
1/8 improved markedly, 
2/8 improved somewhat, 
1/8 no improvement.  
In placebo-treated patients 
1/8 showed a little 
improvement, 7/8 showed 
no change.   
Carlini & 
Cunha (1981) 
Small (15), adult patient cohort all 
with partial seizures with secondary 
generalisation that were 
unresponsive to conventional 
treatment; double blind study 
design employing CBD and 
placebo.  
Clinical 
trial 
Oral 
CBD 
(200-300 
mg per 
day) 
No change 
No significant change to 
seizure incidence 
Ames & 
Cridland 
(1986) 
Findings only published in abstract 
form which yields limited 
information; 12 patients enrolled; 
CBD given as an adjunct to existing 
treatments.  
Survey 
of 
cannabis 
use in 
patients 
admitted 
to 
hospital 
after first 
seizure 
Cannabis 
Anti-
convulsant 
The authors concluded that 
„marijuana use [is] a 
protective factor for new-
onset seizures‟ 
Ng et al., 
(1990) 
Survey of 308 patients admitted to 
hospital after first seizure compared 
to 294 control patients with no 
seizure; the results were criticised 
as „weak‟ by a 1999 US Institute of 
Medicine report „Marijuana and 
medicine: Assessing the science 
base‟ since „the study did not 
include measures of health status 
prior to hospital admissions and 
differences in their health status 
might have influenced their drug 
use'  
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Clinical 
trial 
CBD 
(900-
1200 mg 
per day 
for 10 
months) 
Anti-
convulsant 
„seizure frequency was 
markedly reduced in the 
patient‟ 
Trembly & 
Sherman 
(1990) 
 
 
Open label clinical trial; Results 
presented at conference and cited 
in: British Medical Association. 
Therapeutic uses of cannabis. 
Harwood Academic Publishers, 
Amsterdam, 1997; p51 
Case 
studies 
Cannabis 
Anti-
convulsant 
Qualitative reports of 
successful seizure control 
with cannabis in three 
epilepsy patients  
Grinspoon & 
Bakalar 
(1997) 
 
Case 
studies 
Cannabis 
Anti-
convulsant 
Qualitative reports of 11 
patients successfully self-
treating seizures with 
cannabis  
Petro (1997) 
Patients identified as applicants to 
the US Compassionate Use 
Investigational New Drug 
Programme to provide legal 
medical exemption from 
prosecution for cannabis possession 
and use. 
Survey Cannabis 
Anti-
convulsant 
4% of patients supported 
by a medical marihuana 
programme reported use 
for seizure control 
Corral (2001) Survey population size: 77 
Survey Cannabis 
Anti-
convulsant 
1% of clinical cannabis 
users in California reported 
use for seizure control  
Gieringer 
(2001) 
Survey population size: ~2500 
Survey 
Cannabis 
and 
9
-
THC 
Anti-
convulsant 
1.4% of German medical 
users of cannabis and THC 
reported use for seizure 
control 
Grotenhermen 
& Schnelle 
(2003) 
Survey population size: 143 
Case 
studies 
9
-THC 
Anti-
convulsant 
„Anticonvulsive action‟ Lorenz (2004) 
0.04–0.12 mg/kg administered 
orally 
Survey Cannabis 
Anti-
convulsant 
„The majority of active 
users [reported] beneficial 
effects on seizures‟ 
Gross et al., 
(2004) 
Telephone survey of epilepsy 
patients 
Survey Cannabis 
Anti-
convulsant 
Dutch Ministry of Health 
ordered (1999) monitoring 
of 
9
-THC content of all 
legally supplied cannabis 
following reports of 
reduced seizure duration 
and incidence in cannabis 
users. 
Pijlman et al. 
(2005) 
 
Clinical 
trial 
 
9
THC 
/CBD 
(Sativex) 
Pro-
convulsant 
Four patients experienced 
„first ever seizures‟ 
Wade et al. 
(2006) 
Open label clinical trial in multiple 
sclerosis patients 
Case 
study 
Cannabis 
Anti-
convulsant 
„Marked improvement‟ in 
seizure control following 
marijuana use 
Mortati et al. 
(2007) 
Adult cerebral palsy patient 
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